Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
21 participants
INTERVENTIONAL
2014-12-02
2016-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
The allocation was 1:1 concealed and done by simple randomization using a table of random numbers. After randomization, 11 patients received of ASA 300 mg once daily and 10 patients received placebo (calcined magnesia) in the same pharmacological presentation for 90 days, the dose was based in the non-affectation of renal uric acid resorption.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acetylsalicylic acid
The patients were randomly assigned to received Acetylsalicylic acid 300 mg once daily for 90 days
Acetylsalicylic acid
Acetylsalicylic acid 300 mg per capsule
calcined magnesia
The patients were randomly assigned to received placebo (calcinaned magnesia),
1 capsule 300 mg before each meal for a period of 90 days.
Calcined magnesia
Calcined magnesia 300 mg per capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acetylsalicylic acid
Acetylsalicylic acid 300 mg per capsule
Calcined magnesia
Calcined magnesia 300 mg per capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 25.0 - 35.0 kg/m2
* HbA1c between 6.5 - 9%.
* Written informed consent
* Same residential area and socioeconomic status.
Exclusion Criteria
* Nonsmokers.
* Body weight was stable for al last 3 months before the study.
* Personal history of hepatic, renal, gastric or coronary artery disease.
* Hypersensibility to acetylsalicylic acid.
35 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centro Universitario de Ciencias de la Salud, Mexico
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sara Pascoe Gonzalez
PhD Clinical Research
References
Explore related publications, articles, or registry entries linked to this study.
Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des. 2008;14(10):979-86. doi: 10.2174/138161208784139684.
Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005 Aug;59(7):365-73. doi: 10.1016/j.biopha.2005.07.002.
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545.
Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med. 2011 Sep 1;51(5):993-9. doi: 10.1016/j.freeradbiomed.2010.12.005. Epub 2010 Dec 13.
Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2005 Apr 29;4:5. doi: 10.1186/1475-2840-4-5.
Zatalia SR, Sanusi H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Med Indones. 2013 Apr;45(2):141-7.
Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, Morgan D, Oliveira-Emilio HC, Carpinelli AR, Curi R. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007 Aug 15;583(Pt 1):9-24. doi: 10.1113/jphysiol.2007.135871. Epub 2007 Jun 21.
Lapshina EA, Sudnikovich EJ, Maksimchik JZ, Zabrodskaya SV, Zavodnik LB, Kubyshin VL, Nocun M, Kazmierczak P, Dobaczewski M, Watala C, Zavodnik IB. Antioxidative enzyme and glutathione S-transferase activities in diabetic rats exposed to long-term ASA treatment. Life Sci. 2006 Oct 4;79(19):1804-11. doi: 10.1016/j.lfs.2006.06.008. Epub 2006 Jun 15.
Baltazar MT, Dinis-Oliveira RJ, Duarte JA, Bastos ML, Carvalho F. Antioxidant properties and associated mechanisms of salicylates. Curr Med Chem. 2011;18(21):3252-64. doi: 10.2174/092986711796391552.
Caballero F, Gerez E, Batlle A, Vazquez E. Preventive aspirin treatment of streptozotocin induced diabetes: blockage of oxidative status and revertion of heme enzymes inhibition. Chem Biol Interact. 2000 Jun 1;126(3):215-25. doi: 10.1016/s0009-2797(00)00168-x.
Jeyaseelan L, Rao PS. Methods of determining sample sizes in clinical trials. Indian Pediatr. 1989 Feb;26(2):115-21.
Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.
Blakytny R, Harding JJ. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp Eye Res. 1992 Apr;54(4):509-18. doi: 10.1016/0014-4835(92)90129-g.
Coudray C, Favier A. Determination of salicylate hydroxylation products as an in vivo oxidative stress marker. Free Radic Biol Med. 2000 Dec;29(11):1064-70. doi: 10.1016/s0891-5849(00)00403-2.
Ames PR, Batuca JR, Muncy IJ, De La Torre IG, Pascoe-Gonzales S, Guyer K, Matsuura E, Lopez LR. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. Thromb Res. 2012 Sep;130(3):350-4. doi: 10.1016/j.thromres.2012.03.025. Epub 2012 Apr 20.
Lemkes BA, Bahler L, Kamphuisen PW, Stroobants AK, Van Den Dool EJ, Hoekstra JB, Nieuwland R, Gerdes VE, Holleman F. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. J Thromb Haemost. 2012 Apr;10(4):639-46. doi: 10.1111/j.1538-7836.2012.04632.x.
Muller KA, Chatterjee M, Rath D, Geisler T. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost. 2015 Aug 31;114(3):498-518. doi: 10.1160/TH14-11-0947. Epub 2015 Jul 30.
Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T. Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol. 2014 Mar 19;6:51-9. doi: 10.2147/CPAA.S47895. eCollection 2014.
Dzeshka MS, Shantsila A, Lip GY. Effects of Aspirin on Endothelial Function and Hypertension. Curr Hypertens Rep. 2016 Nov;18(11):83. doi: 10.1007/s11906-016-0688-8.
Grimaldi R, Bisi M, Lonni E, Beggiato E, Valpreda A, Lococo MF, Dosio E, Presutti DG, Tagliabue M, Gaita F. Laboratory aspirin resistance reversibility in diabetic patients: a pilot study using different pharmaceutical formulations. Cardiovasc Drugs Ther. 2014 Aug;28(4):323-9. doi: 10.1007/s10557-014-6536-7.
Abdin AA, Baalash AA, Hamooda HE. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. J Diabetes Complications. 2010 May-Jun;24(3):168-78. doi: 10.1016/j.jdiacomp.2009.01.005. Epub 2009 Mar 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2345
Identifier Type: -
Identifier Source: org_study_id